Podcasts about cutaneous

Soft outer covering organ of vertebrates

  • 159PODCASTS
  • 269EPISODES
  • 29mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Dec 30, 2024LATEST
cutaneous

POPULARITY

20172018201920202021202220232024


Best podcasts about cutaneous

Latest podcast episodes about cutaneous

Journal of Clinical Oncology (JCO) Podcast
JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing

Journal of Clinical Oncology (JCO) Podcast

Play Episode Listen Later Dec 30, 2024 9:01


In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on  "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations" by Dilawari et al published in the Journal of Clinical Oncology.  TRANSCRIPT Giselle Carvalho: Hello and welcome to JCO Article Insights episode for the December issue of the Journal of Clinical Oncology. I'm your host Giselle Carvalho, Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers and one of the ASCO Editorial Fellows at JCO this year. Today, I will be discussing two articles. The first one is “Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies,” and the second one is the “US FDA Approval Summary on Capivasertib with Fulvestrant  for HR-positive HER2-negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alteration.”  As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of patients with luminal metastatic disease is a CDK4/6 inhibitor in combination with endocrine therapy. However, as new endocrine and targeted therapies gain approval, choosing the best systemic therapy upon disease progression after frontline therapy is a topic of ongoing debate. Nearly 40 to 50% of HR-positive breast cancers have actionable genomic alterations and molecular testing should be a routine recommendation for patients with metastatic HR-positive HER2-negative disease. This can be performed repeating tissue biopsy at the time of progression or from archival tissue. Treatment options after progression on CDK4/6 inhibitors include alpelisib in combination with fulvestrant in patients with PIK3CA mutant tumors as seen in the SOLAR-1 trial, or capivasertib with fulvestrant in patients with a tumor mutation in (PI3K)–AKT–PTEN pathway as seen in the CAPItello-291 study, which will be discussed further.  In approximately 30% of patients, progression on frontline endocrine plus CDK4/6 inhibitor treatment is caused by endocrine resistance, frequently involving activating mutations in ESR1. For those tumors, elacestrant, an oral SERD is an option as demonstrated in the EMERALD trial. For patients with a BRCA mutation, PARP inhibitors represent another option. If no mutations are detected, everolimus, an mTOR inhibitor, can be used based on the BOLERO-2 results. The phase 2 MAINTAIN and PACE trials, along with the phase 3 postMONARCH trial support changing the endocrine therapy backbone with or without switching the CDK4/6 inhibitor. In less resourced areas, fulvestrant monotherapy is still an option to delay cytotoxic chemotherapy, though its efficacy is limited when used as a single agent. Finally, after progression on at least one line of chemotherapy, antibody drug conjugates including sacituzumab govitecan or trastuzumab deruxtecan may be an option.  Now focusing on the PI3K AKT PTEN signaling pathway, activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN occur in approximately half of luminal breast cancers. In June 2023, the CAPItello-291 trial was published and treatment with fulvestrant plus capivasertib, a PTEN AKT inhibitor, demonstrated a 3.6 month PFS benefit compared to fulvestrant alone, regardless of the presence of AKT pathway alterations. However, for those with tumors without AKT pathway alteration, an exploratory analysis showed that although there was a numerical improvement in PFS, it did not meet statistical significance, indicating that the biomarker positive population primarily drove the positive results noted in the overall population. Therefore, capivasertib plus fulvestrant was approved by the US FDA in November 2023 exclusively for patients with PI3K/AKT1/PTEN tumor alterations after progression on an aromatized inhibitor with or without a CDK4/6 inhibitor. The approved schedule of capivasertib is slightly different from that of other agents used in breast cancer. It is 400 milligrams taken orally twice a day for four days per week every week in a 28-day cycle in combination with fulvestrant. Diarrhea, rash and hyperglycemia were the most commonly reported grade three or four adverse events in the interventional group. I would like to highlight that even though the CAPItello trial excluded patients with glycosylated hemoglobin levels higher than 8% or those diagnosed with diabetes who required insulin, hyperglycemia occurred in 19% of biomarker positive patients treated with capivasertib, with nearly 2% of this population experiencing grade 3 or 4 hyperglycemia and some patients experiencing life threatening outcomes such as diabetic ketoacidosis.  By way of comparison, hyperglycemia of any grade was three times higher with alpelisib therapy in the SOLAR-1 trial, occurring in 64% of the patients and grade three or higher hyperglycemia was seen in 37% of the patients. Diarrhea was the most common treatment related adverse event experienced by 77% of the biomarker positive population. Prompt use of the antidiarrheal drugs when needed, such as loperamide must be encouraged as untreated diarrhea can lead to dehydration and renal injury. Cutaneous rash occurred in 56% of the biomarker positive population in the interventional group and 15% experienced a grade 3 or 4 rash. Nearly half of the patients with cutaneous adverse reactions required treatment and this was the leading reason for dose reduction of capivasertib.  In the biomarker positive population, the improvement in medium PFS were 4.3 months by investigator assessment. Overall survival data from the CAPItello-291 trial is still immature, but quality of life data was recently published in September this year and was assessed by the 30 item QLQ C30 questionnaire and the QLQ BR23, the breast module. According to Oliveira et al, global health status and quality of life were maintained for a longer period with capivasertib fulvestrant than with placebo fulvestrant except for symptoms of diarrhea which were significantly worse in the capivasertib group. The median time of deterioration of global health status and quality of life was twice as long in the capivasertib group being almost 25 months versus 12 months in the placebo fulvestrant group. These data reinforced the use of capivasertib in combination with fulvestrant for the treatment of HR-positive HER2-negative advanced breast cancer patients with PIK3CA/AKT1/PTEN tumor alterations who have progressed after an aromatase inhibitor-based therapy with or without a CDK4/6 inhibitor.  Thank you for listening to JCO Article Insights. This is Giselle Carvalho. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. See you next time.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Clippings: The Official Podcast of the Council for Nail Disorders
Nail Discoloration following the Chronic use of Skin-Depigmenting Creams; Nail Pigmentation may be an Early Sign of Minocycline associated Cutaneous Pigmentation

Clippings: The Official Podcast of the Council for Nail Disorders

Play Episode Listen Later Nov 30, 2024 14:02


Nail Discoloration following the Chronic use of Skin-Depigmenting Creams. Bandara M. Liyanage A. Cureus. 2024 Aug 25; 16(8):e67770Nail Pigmentation May Be an Early Sign of Minocycline Associated Cutaneous Pigmentation: A Systemic Review. Axler E, Malik S, Lu A, Hong S, Desai AD, Malik S, Lipner SR. JAAD. 2024 Aug 26:S0190-9622(24)

Rare Disease, Cell & Gene Therapy Weekly RoundUp
Innovative Treatments for Cutaneous T-Cell Lymphoma with Leonard Mazur of Citius Pharmaceuticals

Rare Disease, Cell & Gene Therapy Weekly RoundUp

Play Episode Listen Later Nov 19, 2024 26:21


Welcome to this month's P4A Let's Talk Rare podcast episode by Partners4Acess. Today, Georgie and Owen are joined by Leonard Mazur, CEO of Citius Pharmaceuticals, to discuss their innovative therapy, Lymphir, for cutaneous T-cell lymphoma (CTCL). Leonard shares his journey with Citius, from its founding in 2013 to the recent resubmission of Lymphirto the FDA, and discusses the drug's potential to alleviate severe itching for the 21,000 annual CTCL patients in the U.S. The conversation also covers Citius's commercialisation plans and ongoing trials exploring Lymphir's use for other conditions. Join Georgie, Leonard, and co-host Owen for an insightful discussion on how Citius is committed to improving patient quality of life through groundbreaking treatments! Leonard explains how Citius acquired Lymphir in 2021, a drug facing regulatory challenges that they've addressed for FDA resubmission, with potential approval expected. They discuss Lymphir's benefits, especially for CTCL patients, including its potential to relieve severe itching and outline the company's commercialisation plans with Eversana. Leonard emphasises the team's extensive expertise as vital to navigating the regulatory process. They also explore Lymphir's off-label potential for other cancers, with ongoing trials at major universities. The conversation closes on the rewarding impact of pharmaceutical work on patient lives, underscoring Citius's commitment to addressing unmet medical needs through innovative treatments. Leonard Mazur Bio: Leonard Mazur is a seasoned entrepreneur and executive with over five decades of experience in the pharmaceutical industry. He is known for his skill in founding and growing multiple healthcare companies. Currently CEO of Citius Pharmaceuticals, Leonard previously co-founded Leonard-Meron Biosciences and Akrimax Pharmaceuticals. He also led Triax Pharmaceuticals as COO, specialising in dermatology, and successfully sold his dermatological company, Genesis Pharmaceuticals, to Pierre Fabre in 2003. His extensive background spans roles in sales, marketing, and business development at Medicis, ICN, Knoll Pharma, and Cooper Labs. Born in Germany, Mazur holds an MBA from Temple University, where he also earned his undergraduate degree. He is an Ellis Island Medal of Honor recipient. Episode Resources: Leonard Mazur on LinkedIn Citius Pharmaceuticals Website Owen Bryant on LinkedIn Georgina Rack on LinkedIn Partners4Access Website  P4A Let's Talk Rare podcast on Apple Podcasts

CME in Minutes: Education in Primary Care
Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

CME in Minutes: Education in Primary Care

Play Episode Listen Later Nov 6, 2024 15:35


Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

CME in Minutes: Education in Dermatology
Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

CME in Minutes: Education in Dermatology

Play Episode Listen Later Nov 6, 2024 15:35


Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.

AAD's Dialogues in Dermatology
November JAAD Series: Early Post-Operative Water Exposure Does Not Increase Complications in Cutaneous Surgeries: A Randomized, Investigator-Blinded, Controlled Trial

AAD's Dialogues in Dermatology

Play Episode Listen Later Nov 1, 2024


The Derm Vet Podcast
244. Spoooooky derm tips

The Derm Vet Podcast

Play Episode Listen Later Oct 31, 2024 17:58


Happy Halloween!I asked for your spooky derm concerns and you delivered! Check out our top 5 sppoookkkyyy derm tips on this week's episode of The Derm Vet podcast.1. Combining immunosuppressive drugs2. Feline otitis3. Cutaneous lymphoma4. Missteps that can haunt you5. Pseudomonas otitisTIMESTAMPS00:00 Intro01:08 Concern with Combining Immunosuppressive Medications05:46 Treating Feline Otitis08:11 Cutaneous Lymphoma10:25 What is a common misstep that can haunt a practitioner?14:28 Pseudomonas Otitis16:42 Outro

I'd Love to Know
Understanding Skin Health and Advanced Dermatology with Murad Alam, MD

I'd Love to Know

Play Episode Listen Later Sep 27, 2024 58:51


Today we focus on the skin, with a wide ranging conversation featuring Northwestern Department of Dermatology's, Murad Alam, MD. Dr. Alam discusses aging, the role of UV exposure, skin cancer types and treatments, including Mohs surgery, and the latest in skin tightening and fillers. We also cover recent advancements in AI for skin cancer detection, the safety of sunscreen ingredients, and the potential of laser therapy and noninvasive procedures in aesthetic medicine.Dr. Alam is Vice Chair, Chief of Cutaneous and Aesthetic Surgery, and a professor in the Department of Dermatology at Northwestern University's Feinberg School of Medicine. He graduated from Yale for both undergrad and medical school and did his residency at Columbia University. He has also earned an MSCI from Northwestern and an MBA from their Kellogg School of Management. Dr. Alam has served as president of the Dermatologic Surgery Society, the American Society of Laser Medicine, and on the editorial board of the Journal of the American Academy of Dermatology. He is an accomplished author, with over 400 peer-reviewed scientific publications.(00:41) Introducing Dr. Murad Alam(03:20) Understanding Dermatology and Dermatologic Surgery(04:18) Types and Causes of Skin Cancer(11:46) Treatment Options for Skin Cancer(18:27) Advancements in Skin Cancer Treatment(22:10) Artificial Intelligence in Dermatology(26:33) When to See a Dermatologist(28:26) Improving Surgical and Traumatic Scars(32:42) Skin Tightening Procedures: Ultrasound, Radio Frequency, and Infrared(37:55) Fillers: Types, Techniques, and Safety(48:30) Low Light Therapy: Benefits and Home Devices(54:17) Sunscreen Safety and FDA Recommendations(56:30) Stem Cell TreatmentsIf there are topics that you are interested in learning more about, please visit MichaelJLeeMD.com.If you'd like to receive new episodes as they're published, please follow I'd Love to Know in Apple Podcasts, Spotify, or wherever you get your podcasts. If you enjoyed this episode, please consider leaving a review on Apple Podcasts or Spotify. It really helps others find the show.The information from this podcast does not constitute medical advice and is meant for basic informational purposes only. If you're interested in pursuing any of the therapies, supplements, or medications discussed here, please consult with your physician.Podcast episode production by Dante32.

JAMA Network
JAMA Dermatology : Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

JAMA Network

Play Episode Listen Later Aug 28, 2024 18:51


Interview with Kavita Y. Sarin, MD, PhD, author of Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment
Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment

Play Episode Listen Later Aug 28, 2024 18:51


Interview with Kavita Y. Sarin, MD, PhD, author of Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

The Derm Vet Podcast
234. Oncologist Opinion: Cutaneous lymphoma

The Derm Vet Podcast

Play Episode Listen Later Aug 22, 2024 22:19


Cutaneous lymphoma can be a tricky disease. It is red, flaky and itchy just like allergies can be. If you see an older dog with these lesions, it should be a differential. But, what do you do if you get back a biopsy of cutaneous lymphoma? What if you can't refer the case to an oncologist?Today's post welcomes Rachel Venable, DVM, MS, DACVIM (oncology) to discuss this disease and what you can do to manage them. She is the founder of Pet Cancer Care Consulting which is a teleconsulting service. Dr. Venable talks about diagnosis, prognosis and various treatment protocols regarding cutaneous lymphoma.TIMESTAMPSIntro 00:00What Oncologists See With Epitheliotropic Lymphoma 02:00The Prognosis Of Epitheliotropic Lymphoma 05:45Does Dr. Venable Do Staging? 09:50The Difference Between B-Cell And T-Cell Lymphoma 11:28Walking Through Different Scenarios 12:58The Concern Of Apoquel Neoplasia 19:00Outro 21:44

Oncology Brothers
How to treat Cutaneous Melanoma (Skin Cancer) - Dr. Allison Betof Warner

Oncology Brothers

Play Episode Listen Later Aug 8, 2024 26:08


In this episode of the Oncology Brothers podcast, Dr. Allison Betof Warner from Stanford University joins hosts Drs. Rahul and Rohit Gosain discuss the current standard of care and recent advances in cutaneous melanoma treatment. Key Points Covered: •⁠  ⁠Early Stage Melanoma: Discussion on the standard of care for different stages, including the role of neoadjuvant immunotherapy. •⁠  ⁠Adjuvant Therapy: Controversies and considerations for stage 2 and beyond, including the use of ctDNA as a predictive tool. •⁠  ⁠Neoadjuvant Therapy: Insights into recent trials and the evolving landscape of neoadjuvant treatment for melanoma. •⁠  ⁠Metastatic Stage: Exploration of treatment options, including immunotherapy combinations and BRAF MEK inhibitors. •⁠  ⁠TILS Therapy: Overview of the recent approval of Tumor Infiltrating Lymphocytes (TILS) therapy for melanoma patients. Stay informed on the latest in melanoma treatment by listening to this insightful discussion with Dr. Warner. Don't miss out on valuable insights that can impact patient care and treatment decisions. Subscribe now to the Oncology Brothers podcast for more updates on oncology practices and advancements.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

the word is leadership
episode 31 - the word is cutaneous

the word is leadership

Play Episode Listen Later Aug 4, 2024 15:11


In the 31st episode of ‘The Word is Leadership' I recall my nephew Evan's advice on avoiding analogies that might use future words as I use our random word ‘cutaneous' to explore the concept of authenticity I argue that while authenticity pertains to surface-level consistency, it is integrity with its alignment between thoughts, words, and deeds that followers want. I emphasise that, like healthy skin, leadership requires permeability, allowing others to understand their motives while continually improving themselves. Being oneself is important, but it should involve conscious effort and skilful adaptation, not mere complacency. Ultimately, my aim is to challenge the notion that leadership is superficial, urging leaders to consider whether their "skin" serves as a connector or a disguise.

The Cutaneous Connection
S2 Ep17: The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection

Play Episode Listen Later Aug 2, 2024 3:19


We recently caught up with Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, at the 2024 Society for Pediatric Dermatology Annual Meeting. Lio presented a session on changing the disease course in pediatric atopic dermatitis, alongside Amy Paller, MD. We'll dive into the highlights of their talk, the role of disease progression, and the exciting pipeline ahead.

JAMA Network
JAMA Dermatology : Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

JAMA Network

Play Episode Listen Later Jul 24, 2024 13:54


Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment
Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment

Play Episode Listen Later Jul 24, 2024 13:54


Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Relationships & Revenue with John Hulen
Episode 219 The Skin Whisperer with Dr. Keira Barr (Part 1)

Relationships & Revenue with John Hulen

Play Episode Listen Later Jul 12, 2024 35:31


John talks with Dr. Keira Barr — a dual board-certified dermatologist, menopause specialist, author of The Skin Whisperer: A Dermatologist Reveals How to Look Younger, Radiate Beauty, and Live the Life You Crave, speaker, educator, skin cancer survivor, wife, and mom. The two discuss the interconnectedness between the mind, body, and skin and the importance of taking a holistic approach to health and wellness. Listen to this episode to learn more: [00:00] - Intro [01:57] - Dr. Keira's background  [04:29] - Dr. Keira's journey into integrative and functional medicine [07:16] - John's perspective on health [09:13] - “The Skin Whisperer” book [15:09] - Skincare audit to assess overall well-being [18:05] - Relationship between stress, inflammation, and immune system [19:14] - NICE (Neuro, Immune, Cutaneous, Endocrine) system [20:38] - Impact of personal authenticity on relationships and health [23:29] - Inflammation and impact on overall health [27:34] - Dr. Keira's plans to collaborate with psychiatrists [31:20] - Study shows 98% of people with skin issues report mental health impacts [32:51] - John's fascination with neuroscience [34:49] - Observing body language to enhance self-awareness and relationships NOTABLE QUOTES: “Your skin is a reflection of your internal health. So, what you see on the surface of your skin is an invitation to get really curious about what's happening in your life.” “Everything in your environment that can impact how your skin functions, how your body functions, and how you function in your skin is in relationship with each other.” “Most people go around thinking there's something wrong with them; I must be broken. And you're not broken. You just maybe have been misinformed. Maybe no one told you. And there's an opportunity to learn.” “Health is really about the integration of mental, emotional, and spiritual well-being.” “What you see on your skin is an invitation from your body to get really curious about what's happening in your life, in your relationships, with the environment that you're in, and the products that you're using.” “Our body has its own language. And the invitation is, can you be open and willing to learn the language of your body? Because that is the key to the kingdom of enhancing your relationships,  relationship with your first year yourself first, and then your relationship with others.” USEFUL RESOURCES: https://drkeirabarr.com  https://www.linkedin.com/in/keirabarr/  https://www.instagram.com/drkeirabarr https://www.facebook.com/drkeirabarr/ https://www.youtube.com/@keirabarr7540 The Skin Whisperer: A Dermatologist Reveals How to Look Younger, Radiate Beauty and Live the Life You Crave - https://a.co/d/b9ocbrG CONNECT WITH JOHN Website - https://thejohnhulen.com  Instagram - https://www.instagram.com/johnhulen  Facebook - https://www.facebook.com/johnhulen  Twitter - https://www.twitter.com/johnhulen   LinkedIn - https://www.linkedin.com/in/johnhulen     YouTube - https://www.youtube.com/channel/UCLX_NchE8lisC4NL2GciIWA  EPISODE CREDITS Intro and Outro music provided by Jeff Scheetz - https://jeffscheetz.com/ 

Outbreak News Interviews
Colombia: The incidence of cutaneous leishmaniasis has decreased by 45% in the last 10 years

Outbreak News Interviews

Play Episode Listen Later Jul 7, 2024 8:40


In this newscast, I look at the parasitic disease, leishmaniasis and the current situation in Colombia.

Dermasphere - The Dermatology Podcast
133. Dr. Feldman on THE CURSE OF KNOWLEDGE - Doxycycline is better than minocycline - Psychoactive meds in pruritus - Anifrolumab for cutaneous JDM

Dermasphere - The Dermatology Podcast

Play Episode Listen Later Jun 11, 2024 55:51


Dr. Feldman on THE CURSE OF KNOWLEDGE - Doxycycline is better than minocycline - Psychoactive meds in pruritus - Anifrolumab for cutaneous JDM - Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: https://www.youtube.com/@dermaspherepodcast and VuMedi!: https://www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠https://physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠https://dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: https://www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!

JDD Podcast
From Cutaneous Microbiota to Clinical Trial Recruitment… Diversity Matters

JDD Podcast

Play Episode Listen Later May 17, 2024 25:04


Unless you have been under a pile of retention hyperkeratosis, it would be hard to say one has not heard the call to purposefully diversify clinical trial programs to ensure... The post From Cutaneous Microbiota to Clinical Trial Recruitment… Diversity Matters appeared first on JDDonline - Journal of Drugs in Dermatology.

Connecticut Children's Grand Rounds
5.10.24 Ask the Experts, "Red Flags: Cutaneous Vascular Lesions in Childhood", Richard Joseph Antaya, MD

Connecticut Children's Grand Rounds

Play Episode Listen Later May 10, 2024 55:08


Event Objectives:Identify and understand the physiology for the two most common vascular lesions of infancy and childhood infantile hemangiomas and capillary malformations.Familiarize with the complications and treatment for hemangiomas in specific locations.Understand the treatment timing and expected results for capillary malformations and hemangiomas including beta-blockers.Recognize “red flags” on the skin which demand further evaluation and have potential for serious morbidity.Claim CME Credit Here!

Evidence Based Hair
"Unraveling the Link Between Dupilumab and Cutaneous T-Cell Lymphoma"

Evidence Based Hair

Play Episode Listen Later Apr 22, 2024 20:13 Transcription Available


Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed? Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.   While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it. As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL.  Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.     donovanmedical  Edited• Season 7 of the Evidence Based Hair Podcast has started. This week I review several fascinating studies: The podcast can be accessed wherever you listen to your podcasts or via the DonovanMedical youtube channel. REFERENCES IN THIS EPISODE   Hasan I et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566-8. doi: 10.1016/j.jaad.2024.03.039. Online ahead of print. Jfri A et al. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol . 2023 May;88(5):1164-1166. doi: 10.1016/j.jaad.2022.12.001. Epub 2022 Dec 5. Espinosa ML et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol . 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27.

AAD's Dialogues in Dermatology
February JAAD: Bridging the Specialty Gap: Update on Primary Cutaneous Lymphomas

AAD's Dialogues in Dermatology

Play Episode Listen Later Mar 20, 2024


Elise Olsen, MD, FAAD interviewed by Vineet Mishra, MD, FAAD

Neurology Minute
Cutaneous Phosphorylated Alpha-Synuclein Deposition in Dementia

Neurology Minute

Play Episode Listen Later Mar 19, 2024 4:49


Dr. Jason Crowell talks with Dr. Christopher Gibbons to discuss his paper "Cutaneous Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies and Mild Cognitive Impairment."   Show reference:  https://index.mirasmart.com/AAN2024/SearchResults.php?Program_Number=PL4.004

Two Onc Docs
Non-Melanoma Cutaneous Malignancies

Two Onc Docs

Play Episode Listen Later Mar 4, 2024 11:41


This week's episode will be focusing on cutaneous malignancies other than melanoma including squamous cell skin cancer and basal cell carcinoma. We will go over the important details on staging, diagnosis, & treatment options. 

This Week in Parasitism
TWiP 230: Healing cutaneous leishmaniasis with Maria Adelaida Gomez

This Week in Parasitism

Play Episode Listen Later Mar 1, 2024 60:47


Maria Adelaida Gomez joins TWiP to discuss her career and the work of her laboratory on understanding the healing process during cutaneous leishmaniasis. Hosts: Vincent Racaniello, Dickson Despommier, Daniel Griffin, and Christina Naula Guest: Maria Adelaida Gomez Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode CIDEIM Healing in cutaneous leishmaniasis (J Immunol) Become a patron of TWiP Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

CME in Minutes: Education in Primary Care
Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

CME in Minutes: Education in Primary Care

Play Episode Listen Later Feb 26, 2024 18:19


Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

CME in Minutes: Education in Dermatology
Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

CME in Minutes: Education in Dermatology

Play Episode Listen Later Feb 26, 2024 18:19


Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

PeDRA Pearls
Monday Re-release: Points of Discussion - EM, RIME, SJS-TEN: The Alphabet Soup of Blistering Severe Cutaneous Adverse Reactions

PeDRA Pearls

Play Episode Listen Later Jan 22, 2024 64:53


The Drugs and Bugs Focused Study Group presents a spirited conversation on whether Reactive Infectious Mucocutaneous Eruption (RIME) should be a separate condition from Stevens-Johnson Syndrome (SJS). Moderated by Dr. Michele Ramien, Dr. Erin Mathes, and Dr. Yvonne Chiu debate RIME, SJS, and other blistering severe cutaneous adverse reactions. In this three-part miniseries, episode one presents the case for RIME, episode 2 states the case for SJS, and episode three is a moderated discussion between the two opposing sides to highlight the research still needed to come to a consensus, while also shedding light on active research in this area. The program originally aired in June of 2023.

PeDRA Pearls
Monday Re-release: Blistering Severe Cutaneous Adverse Reactions in Children

PeDRA Pearls

Play Episode Listen Later Jan 15, 2024 13:43


Blistering severe cutaneous adverse reaction in children: proposal for pediatric-focused clinical criteria. Dr. Michele Ramien summarizes a collaborative study on blistering severe cutaneous adverse reactions (SCAR) in children. It's very important to diagnose these reactions early and accurately as they can be life-threatening. The study created categories that are more appropriate for diagnosing pediatric patients than what existed in the past. Watch to learn more about the impact on patients and the next steps. To view the video version of this program please click here.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 4, 2024 55:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 4, 2024 55:48


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jan 4, 2024 55:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 4, 2024 55:48


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jan 4, 2024 55:48


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PeerView Clinical Pharmacology CME/CNE/CPE Video
April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jan 4, 2024 55:35


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerApril W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.Co-Chair/PlannerTina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

CME in Minutes: Education in Primary Care
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

CME in Minutes: Education in Primary Care

Play Episode Listen Later Jan 3, 2024 14:25


Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

CME in Minutes: Education in Dermatology
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

CME in Minutes: Education in Dermatology

Play Episode Listen Later Jan 3, 2024 14:25


Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

CME in Minutes: Education in Primary Care
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

CME in Minutes: Education in Primary Care

Play Episode Listen Later Dec 18, 2023 14:21


Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

CME in Minutes: Education in Dermatology
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

CME in Minutes: Education in Dermatology

Play Episode Listen Later Dec 18, 2023 14:21


Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Derm Club with Dr. Hannah Kopelman
#28 Cutaneous T Cell Lymphoma (CTCL) | Dr. Michael Girardi

Derm Club with Dr. Hannah Kopelman

Play Episode Listen Later Nov 28, 2023 31:48


Today we are doing a deep dive into Cutaneous T Cell Lymphoma (CTCL). This uncommon yet impactful skin condition takes center stage as we seek to unravel its complexities. To have this discussion, we are fortunate to have Dr. Michael Girardi, a distinguished dermatologist and a leading authority in the field of CTCL research from Yale University. Together, we'll navigate the intricacies of CTCL, exploring its nuances, diagnosis procedures, available treatment modalities, and the promising advancements that hold the potential to transform the landscape of CTCL management. Dr. Girardi's wealth of knowledge and expertise promises to shed light on this condition, offering hope and understanding to those affected by CTCL and the medical community at large. To learn more about CTCL: https://www.hannahkopelman.com/blog/cutaneous-t-cell-lymphoma/ Connect with me across Social: Twitter: https://twitter.com/drhankopelman Instagram: https://www.instagram.com/doctor.han/ TikTok: https://www.tiktok.com/@drhankopelman Blog: https://www.hannahkopelman.com/blog/ The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hannah-kopelman/message

The Medbullets Step 2 & 3 Podcast
Dermatology | Cutaneous Larva Migrans

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Nov 12, 2023 7:45


In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cutaneous Larva Migrans from the Dermatology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

The Medbullets Step 2 & 3 Podcast
Dermatology | Cutaneous Warts (Verrucae)

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Nov 8, 2023 5:26


In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cutaneous Warts (Verrucae)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠from the Dermatology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

VETgirl Veterinary Continuing Education Podcasts
Diagnosing and Managing Dogs with Cutaneous Adverse Food Reaction (CAFR) with Dr. Jeff Tinsley | VETgirl Veterinary Continuing Education Podcasts

VETgirl Veterinary Continuing Education Podcasts

Play Episode Listen Later Nov 6, 2023 20:40


In today's VETgirl podcast, we interview Dr. Jeff Tinsley from the Animal Dermatology Clinic about how to diagnose and manage dogs with cutaneous adverse food reaction (CAFR). Skin and gastrointestinal (GI) issues are among the most common problems bringing dogs to the veterinary hospital-in fact, a recent clinic survey revealed that nearly 40% of dogs visit the veterinarian because of one of these two complaints-or in some cases both. Do you know what specific clinical signs and patient history typically suggest that you're dealing with a dog with adverse food reactions? What step-by-step diagnostic workup is warranted to rule in or rule out an adverse food reaction? And tune in to find out the most common mistakes made when starting an elimination diet trial!

BackTable ENT
Ep. 135 Cutaneous SCC: Evaluating Risks and Navigating Complex Surgical Reconstruction with Dr. Gina Jefferson

BackTable ENT

Play Episode Listen Later Oct 17, 2023 61:49


The Medbullets Step 2 & 3 Podcast
Oncology | Cutaneous T-Cell Lymphoma

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Oct 14, 2023 8:29


In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cutaneous T-Cell Lymphoma⁠ ⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Oncology Brothers
How to Treat Cutaneous Melanoma - Deep Dive with Dr. Sapna Pate

Oncology Brothers

Play Episode Listen Later Oct 12, 2023 24:05


In discussion with Dr. Sapna Patel, Associate Professor, Director of the Uveal Melanoma, and Melanoma Fellowship Program Director at the MD Anderson Cancer Center we discuss how to treat Cutaneous Melanoma and important nuances from Community Oncology perspective. - Management of Stage 0/IA melanoma - where management is mainly surgery - Who is the most appropriate candidate for lymph node evaluation - Stage IIB and beyond, discussing choice of observation, radiation or immunotherapy especially given recent promising results - In patients with metastatic disease, how to manage BRAF positive vs. negative patient population

Jock Doc Podcast
225. Lateral Cutaneous Nerve of Thigh Neuropathy/Applying to Higher Education

Jock Doc Podcast

Play Episode Listen Later Oct 2, 2023 38:19


Listen as Dr. London Smith (.com) and his producer Cameron discuss Lateral Cutaneous Nerve of Thigh Neuropathy as they share about applying to a higher education.  Sponsored by Caldera + Lab (use code "jockdoc" to get 20% off!). Not so boring! https://calderalab.com/pages/podcast-special-offer?show=Jock+Doc&utm_medium=podcast&utm_source=JocDoc https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Produced by: Dylan Walker Created by: London Smith

Blood Podcast
Dimethyl fumarate in cutaneous T-cell lymphoma, lipid nanoparticles for editing of human hematopoietic cells, and racial and geographic disparities in lymphoma trials

Blood Podcast

Play Episode Listen Later Aug 31, 2023 23:38


In this week's episode, we'll learn more about the treatment of relapsed and refractory cutaneous T-cell lymphoma with dimethyl fumarate, discuss the use of lipid nanoparticles for ex vivo editing of human hematopoietic cells, and learn more about racial and geographic disparities in lymphoma clinical trials.

Neurology Minute
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease

Neurology Minute

Play Episode Listen Later Apr 14, 2023 2:51


Dr. Christopher Gibbons discusses his paper, "Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease". Show references: https://n.neurology.org/content/early/2023/01/19/WNL.0000000000206772 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.